Last reviewed · How we verify
epinephrine inhalation aerosol
Epinephrine inhalation aerosol works by stimulating the beta-2 adrenergic receptors in the lungs to cause bronchodilation.
Epinephrine inhalation aerosol works by stimulating the beta-2 adrenergic receptors in the lungs to cause bronchodilation. Used for Relief of acute bronchospasm in asthma and other obstructive airway diseases.
At a glance
| Generic name | epinephrine inhalation aerosol |
|---|---|
| Also known as | Primatene Mist, Epinephrine Inhalation Aerosol, USP, epinephrine inhalation aerosol - HFA propelled |
| Sponsor | Amphastar Pharmaceuticals, Inc. |
| Drug class | Adrenergic agonist |
| Target | beta-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 3 |
Mechanism of action
This leads to relaxation of bronchial smooth muscle, resulting in increased airflow to the lungs. Epinephrine also has a mild vasoconstrictive effect, which can help reduce nasal congestion.
Approved indications
- Relief of acute bronchospasm in asthma and other obstructive airway diseases
Common side effects
- Tremors
- Nervousness
- Palpitations
Key clinical trials
- Phase 1 Crossover Study Evaluating the Safety, Tolerability, and Pharmacokinetics of KP001 in Healthy Adult Volunteers (PHASE1)
- Pharmacokinetics (PK) Study of Epinephrine Inhalation Aerosol in Healthy Volunteers (PHASE1, PHASE2)
- Evaluation of Efficacy and Safety of E004 in Children With Asthma (PHASE3)
- Randomized, Placebo/Active Crossover Dose-ranging Study for Safety and Efficacy in Asthma Patients. (PHASE1, PHASE2)
- Epinephrine Inhalation Aerosol USP, a HFA-MDI Study for Assessment of Pharmacokinetics (PHASE1, PHASE2)
- Epinephrine Inhalation Aerosol USP, CLINICAL STUDY-B3 FOR ASSESSMENT OF PHARMACOKINETICS (PHASE2)
- Assessment and Evaluation of Pharmacokinetic Profile of E004 in Healthy Adults (PHASE1, PHASE2)
- Epinephrine Inhalation Aerosol USP: For Evaluation Of Efficacy And Safety In Asthma Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- epinephrine inhalation aerosol CI brief — competitive landscape report
- epinephrine inhalation aerosol updates RSS · CI watch RSS
- Amphastar Pharmaceuticals, Inc. portfolio CI